Heartflow Inc. continued the steady rhythm of med-tech companies filing to go public, with an S-1 submitted to the U.S. SEC ...

Health-care companies fell as traders hedged their bets on the outlook for growth in the sector. Insurers, including Elevance, which recently warned of cost pressures from its Affordable Care Act ...

Arbitrators cleared the way for the long-delayed $53 billion acquisition after Exxon tried to pre-empt the deal. 3M raised its full-year earnings outlook after beating expectations in the second ...

GSK was trying to revive a product pulled from US markets in 2022. Its shares fell 4.6 per cent, or 65p, to 1348p.

The panel voted 10-1 to say the available data does not establish the efficacy of the drug, brexpiprazole, in combination ...

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

GSK plc (NYSE:GSK) is one of the best cheap stocks under $50 to buy now. On July 15, BofA analyst Sachin Jain maintained a ...

The FDA oncologic drugs advisory committee voted against the approval of GSK’s blood cancer treatment Blenrep, delivering a setback to the drugmaker’s efforts to reintroduce the drug to the U.S.

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL patients who are not eligible for autologous stem cell transplant, Roche ...

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used ...